News and Trends 21 Jun 2022 Treatment for highly-sensitized kidney transplant patients approved and recommended Treatment offered by Hansa Biopharma for the densensitization of highly sensitized adults prior to kidney transplants from deceased donors has been recommended by the UK’s National Institute for Health and Care Excellence (NICE). NICE considers Idefirix (imlifidase), made by Hansa, a Swedish company that specializes in enzyme technology for rare immunological conditions, to be a […] June 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jun 2022 ImCheck raises €96M in funding round French biotech company ImCheck has announced funding of €96 million ($101.5 million) to investigate antibody drugs with the ability to activate the powerful immune cells called gamma delta T (gdT). The Marseille-based company hopes it will reach a wider range of cancer immunotherapy with the antibody drugs that include a lead candidate in the development […] June 17, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2022 Spirea raises £2.4M to develop antibody drug conjugates in cancer Funding of £2.4 million ($2.9 million) has been secured by UK-based company, Spirea Limited, to advance a new generation of antibody drug conjugate (ADC) therapeutics. The company will use the funds to initiate its pipeline of ADCs in the treatment of solid tumors where they say there is a high unmet need. Targeted therapies, especially […] June 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2021 Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease US regulators have approved the first-in-class drug efgartigimod for the treatment of the rare muscle disease generalized myasthenia gravis, opening up its developer argenx to billion-dollar revenues. Efgartigimod, to be marketed as Vyvgart, is an antibody fragment drug for use in adults with generalized myasthenia gravis. The FDA’s decision represents the first successful drug approval […] December 21, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 25 Nov 2021 Despite New Approvals, Covid-19 Treatments Lag Behind Vaccines The EU recently added two drugs to its list of approved Covid-19 treatments. Yet with vaccines often in the spotlight, treatment options available to doctors remain few. Earlier this month, the European Commission gave its stamp of approval to two antibody treatments for Covid-19: regdanvimab from the South Korean firm Celltrion Healthcare, and a blend […] November 25, 2021 - 6 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2021 GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos Analysts are abuzz over GSK’s co-development deal with immuno-oncology specialist iTeos Therapeutics earlier this month, wondering if it overpaid for the Belgian company’s next-generation checkpoint inhibitor. GSK’s oncology deal with iTeos earlier this month centered on an antibody drug that blocks an immune checkpoint called TIGIT. The candidate is currently in phase I testing for […] June 30, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jun 2021 Scotland’s Top 10 Biotech Companies to Watch Out For Scotland has a thriving life sciences ecosystem with strengths in oncology, genetic engineering, and industrial biotech. Let’s pick up the bagpipes as we tour the top 10 biotech companies in Scotland. Scotland is the UK’s second-most populous country, boasting picturesque scenery, a rich history, and a strong focus on sustainability. There is a diverse range […] June 30, 2021 - 11 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Apr 2020 Swiss and German Team to Develop Inhaled mRNA Coronavirus Treatment The Swiss antibody specialist Neurimmune and the German RNA biotech Ethris are collaborating to develop inhaled messenger RNA (mRNA) antibodies that can treat the catastrophic respiratory effects of coronavirus disease, also known as Covid-19. The therapeutic mRNA would be delivered directly into the lungs of symptomatic patients via nebulizers with nanoparticle aerosols. The mRNA could […] April 2, 2020 - 3 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2020 French Partnership Deploys AI for Antibody Drug Discovery French companies OSE Immunotherapeutics and MAbSilico are teaming up to drive the discovery of new antibody drugs using artificial intelligence. The three-year partnership will use artificial intelligence, or AI, in six programs designed to accelerate the development of therapeutic monoclonal antibodies (mAbs) that can target cancer and autoimmune diseases. AI can improve the efficiency of […] February 13, 2020 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2020 French Biotech Raises €19M to Hit Phase I with Cancer Immunotherapy Alderaan Biotechnology has raised an €18.5M Series A round to push its lead cancer immunotherapy drug to phase I. The UK VC firm Medicxi and the returning French VC investor Advent France Biotechnology contributed to the round. Alderaan, whose name was inspired by a fictional planet in the Star Wars movies, will use part of […] January 9, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 5 Dec 2019 German Biotech Raises €7M Series A to Treat Acute Heart Failure 4TEEN4 Pharmaceuticals has raised a Series A round of €6.9M to fuel the development of a first-in-class antibody drug that could reduce mortality in acute heart failure. The round was led by Brandenburg Kapital, a subsidiary of the German investment bank Investitionsbank des Landes Brandenburg. Other investors in the round, including business angels and private […] December 5, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Sponsored 27 Nov 2019 How to Address the Challenges of Biologics Discovery and Development The biologics industry is growing at an incredible rate. While its global market value was estimated at $236B in 2017, it is expected to rise to $310B by 2023. As key market players enter the field, competition is increasing. In recent years, the biologics industry has become more versatile and has moved from being primarily […] November 27, 2019 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email